Change is on the horizon in the management of uveal melanoma
Novel strategies are offering the possibility of extended patient survival and durable disease control
A novel off-the-shelf cancer vaccine shows some potential in PD-L1-negative patients with advanced melanoma
Although the phase III investigational study with IO102-IO103 plus pembrolizumab is negative, it offers precious insights to advance research in the field
How connecting the dots could deliver a breakthrough in cancer vaccines
After decades of missed promises, cancer vaccines are likely approaching prime time due to major advances in cancer immunobiology, immunotherapy and biomedical technology
Machine learning models predict adverse events and survival in patients receiving immunotherapy
New data supports the use of artificial intelligence for the administration of immune-check inhibitors in solid tumours
Neoadjuvant immunotherapy sets a new standard in stage III melanoma
Next steps for research include personalising regimens and learning how to predict response and toxicity
Studies shed new light on the role of the gut microbiome in immunotherapy toxicity
Results underline the need to further characterise dysbiosis, and to develop diagnostic and actionable tools for mainstream integration
Do young patients benefit from immune checkpoint inhibitors?
First evidence for the efficacy of anti-PD-1 agents in children, adolescents and young adults with melanoma prompts the call for a change in cancer care for this population
A phase I study shows a promising strategy to overcome resistance to immunotherapy in cancer
Safety and efficacy data of a PD-1/IL-2 bispecific antibody fusion protein were presented at an ESMO Virtual Plenary
Anti-cancer vaccine combined with immunotherapy shows promise in melanoma
A phase II trial reports a longer recurrence-free and distant-metastasis free survival with the combination of mRNA and pembrolizumab.
Study shows that immunotherapy initiation at the end of life has increased over time
In US, the trend was more frequently seen at very low-volume and nonacademic centers than at high-volume and academic centers